journal article·2022

Bio-engineered nano-vesicles for IR820 delivery: a therapy platform for cancer by surgery and photothermal therapy

Xiaojie Zhang, Changsheng Zhou, Fanghua Wu, Chang Gao, Qianqian Liu, Peng Lv, Ming Li, Liyong Huang, Ting Wu, Wengang Li

Nanoscale· Volume 14· Issue 7
Publisher page

Abstract

Long-term unsolved health problems from pre-/intra-/postoperative complications and thermal ablation complications pose threats to liver-cancer patients. To reduce the threats, we propose a multimodal-imaging guided surgical navigation system and photothermal therapy strategy to improve specific labeling, real-time monitoring and effective treatment of hepatocellular carcinoma. Using a bioengineering approach, G-Nvs@IR820, a kind of human-cell-membrane nano-vesicle, was generated with growth arrest-specific 6 (Gas6) expressed on the membrane and with near-infrared absorbing dye (IR820) loaded into it, which is proven to be an effective nanoparticle-drug-delivery system for Axl-overexpressing hepatocellular carcinoma. G-Nvs@IR820 shows excellent features in vitro and in vivo. As Gas6 binds to Axl specifically, G-Nvs@IR820 has good targeting ability to the tumor site and also has a good ability to guide the further accurate obliteration of carcinoma from adjacent normal tissue in surgery with its highly resolved fluorescence/photoacoustic/surgical-navigation signals. Moreover, the G-Nvs@IR820 represented a new perspective for photothermal therapy. Briefly, Nvs@IR820 was synthesized at a gram scale with high affinity, specificity, and safety. It has promising potential in clinical application for IGS and PTT in Axl-overexpressing hepatoma carcinoma.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Phagocytosis and Immune Regulation · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Hepatobiliary Surgery, Xiang’an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian 361102, P. R. China

Xiamen University Research Center of Retroperitoneal Tumor Committee of Oncology Society of Chinese Medical Association, Xiamen University, Xiamen, Fujian 361102, P. R. China

Department of Hepatobiliary Surgery, Guizhou Provincial People’s Hospital, Guiyang, Guizhou 550002, P. R. China

Surgery department, Affiliated Fuzhou First Hospital of Fujian Medical University, Fuzhou, Fujian 350009, P. R. China

Cancer Research Center, School of Medicine, Xiamen University, Xiamen, Fujian 361102, P. R. China

Funding

National Natural Science Foundation of China · Xiamen University · Natural Science Foundation of Fujian Province

References (57)

Show source-provided references
1. Yang · Prog. Mater. Sci. · 2020 · 1
2. Parekh · Ther. Delivery · 2018 · 9 · 45110.4155/tde-2018-0013 ↗
3. Liu · Angew. Chem., Int. Ed. · 2018 · 57 · 1249910.1002/anie.201807212 ↗
4. Lv · Nano Lett. · 2019 · 19 · 299310.1021/acs.nanolett.9b00145 ↗
5. Liu · Adv. Mater. · 2019 · 31 · 180829410.1002/adma.201808294 ↗
6. Zhang · Adv. Mater. · 2018 · 30 · 170535010.1002/adma.201705350 ↗
7. Zhang · Biomater. Sci. · 2020 · 8 · 157510.1039/C9BM02088H ↗
8. Zhang · Proc. Natl. Acad. Sci. U. S. A. · 2015 · 112 · E612910.1073/pnas.1505799112 ↗
9. Tian · Adv. Mater. · 2020 · 32 · 190736510.1002/adma.201907365 ↗
10. Tang · Nat. Commun. · 2018 · 9 · 110.1038/s41467-017-02088-w ↗
11. Urade · Asian J. Surg. · 2020 · 43 · 36210.1016/j.asjsur.2019.04.008 ↗
12. Ishizawa · Cancer · 2009 · 115 · 249110.1002/cncr.24291 ↗
13. Liu · Adv. Healthcare Mater. · 2020 · 9 · e190145710.1002/adhm.201901457 ↗
14. Du · Adv. Opt. Mater. · 2019 · 1901471
15. Zhou · Oncotarget · 2016 · 7 · 687810.18632/oncotarget.6901 ↗
16. Fernandez · Int. J. Nanomed. · 2014 · 9 · 463110.2147/IJN.S69550 ↗
17. Dash · Int. J. Mol. Sci. · 2021 · 22 · 665810.3390/ijms22136658 ↗
18. Zhang · ACS Biomater. Sci. Eng. · 2020 · 6 · 587410.1021/acsbiomaterials.0c00921 ↗
19. Li · Cancer Lett. · 2021 · 496 · 16910.1016/j.canlet.2020.09.024 ↗
20. Gao · Mater. Today Bio · 2020 · 5 · 10003510.1016/j.mtbio.2019.100035 ↗
21. Yang · Adv. Sci. · 2020 · 7 · 200108810.1002/advs.202001088 ↗
22. Bienia · Pharmaceutics · 2021 · 13 · 114710.3390/pharmaceutics13081147 ↗
23. Wu · Matter · 2019 · 1 · 49610.1016/j.matt.2019.03.007 ↗
24. Ji · Nat. Commun. · 2021 · 12 · 112410.1038/s41467-021-21436-5 ↗
25. Kong · Nat. Commun. · 2021 · 12 · 477710.1038/s41467-021-24961-5 ↗
26. Larue · Pharmaceuticals · 2019 · 12 · 16310.3390/ph12040163 ↗
27. Ruiz-Esparza · Nano-Micro Lett. · 2021 · 13 · 21210.1007/s40820-021-00712-5 ↗
28. Yang · ACS Nano · 2020 · 14 · 1744210.1021/acsnano.0c07721 ↗
29. Wei · ACS Nano · 2021 · 15 · 542810.1021/acsnano.1c00076 ↗
30. Li · J. Am. Chem. Soc. · 2021 · 143 · 1542710.1021/jacs.1c07875 ↗
31. Meng · Theranostics · 2018 · 8 · 602510.7150/thno.26607 ↗
32. Gao · Nano-Micro Lett. · 2021 · 13 · 9910.1007/s40820-021-00616-4 ↗
33. Liu · Adv. Mater. · 2021 · 33 · 210205410.1002/adma.202102054 ↗
34. Li · Bioact. Mater. · 2021 · 6 · 405310.1016/j.bioactmat.2021.04.014 ↗
35. Tan · ACS Appl. Mater. Interfaces · 2021 · 13 · 3154210.1021/acsami.1c08775 ↗
36. Hu · Small · 2018 · 14 · e180299410.1002/smll.201802994 ↗
37. Dash · Int. J. Mol. Sci. · 2021 · 22 · 665810.3390/ijms22136658 ↗
38. Feneyrolles · Mol. Cancer Ther. · 2014 · 13 · 214110.1158/1535-7163.MCT-13-1083 ↗
39. Chai · Front. Oncol. · 2021 · 11 · 65096310.3389/fonc.2021.650963 ↗
40. Shibata · J. Clin. Invest. · 2020 · 130 · 302110.1172/JCI125505 ↗
41. Zhang · J. Med. Chem. · 2021 · 64 · 395610.1021/acs.jmedchem.0c02093 ↗
42. Lemke · Cold Spring Harbor Perspect. Biol. · 2013 · 5 · a00907610.1101/cshperspect.a009076 ↗
43. Yang · Nat. Rev. Gastroenterol. Hepatol. · 2019 · 16 · 58910.1038/s41575-019-0186-y ↗
44. Hsu · Cancer Med. · 2019 · 8 · 345310.1002/cam4.2229 ↗
45. Liu · PLoS One · 2016 · 11 · e015476710.1371/journal.pone.0154767 ↗
46. Reichl · Hepatology · 2015 · 61 · 93010.1002/hep.27492 ↗
47. Wang · Cell Res. · 2021 · 31 · 12610.1038/s41422-020-00460-y ↗
48. Rabiee · Acta Biomater. · 2019 · 92 · 110.1016/j.actbio.2019.05.018 ↗
49. Ivey · Cancer Lett. · 2016 · 380 · 33010.1016/j.canlet.2015.12.019 ↗
50. Duncan · Nat. Rev. Drug Discovery · 2003 · 2 · 34710.1038/nrd1088 ↗
51. Lee · J. Controlled Release · 2007 · 123 · 1910.1016/j.jconrel.2007.08.006 ↗
52. Zhang · Cancer Res. · 2008 · 68 · 190510.1158/0008-5472.CAN-07-2661 ↗
53. Chen · Biomaterials · 2021 · 268 · 12054110.1016/j.biomaterials.2020.120541 ↗
54. Fernandez-Fernandez · Mol. Imaging · 2012 · 11 · 9910.2310/7290.2011.00031 ↗
55. Chu · Nat. Rev. Cancer · 2014 · 14 · 19910.1038/nrc3672 ↗
56. Huang · Nat. Commun. · 2019 · 10 · 487110.1038/s41467-019-12771-9 ↗
57. Li · Biomaterials · 2016 · 106 · 11910.1016/j.biomaterials.2016.08.016 ↗